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ABSTRACT
The recent interest to modulate autophagy in cancer therapy has been hampered 
by the dual roles of this conserved catabolic process in cancer, highlighting the need for 
tailored approaches. Since RAS isoforms have been implicated in autophagy regulation 
and mutation of the KRAS oncogene is highly frequent in colorectal cancer (CRC), 
we questioned whether/how mutant KRAS alleles regulate autophagy in CRC and its 
implications. We established two original models, KRAS-humanized yeast and KRAS-non-
cancer colon cells and showed that expression of mutated KRAS up-regulates starvation-
induced autophagy in both. Accordingly, KRAS down-regulation inhibited autophagy 
in CRC-derived cells harboring KRAS mutations. We further show that KRAS-induced 
autophagy proceeds via up-regulation of the MEK/ERK pathway in both colon models 
and that KRAS and autophagy contribute to CRC cell survival during starvation. Since 
KRAS inhibitors have proven difficult to develop, our results suggest using autophagy 
inhibitors as a combined/alternative therapeutic approach in CRCs with mutant KRAS.
INTRODUCTION
Colorectal cancer (CRC) is a leading cause of cancer-
related death worldwide [1]. Recent therapies to treat 
metastatic CRC (mCRC) use EGFR pathway inhibitors 
in order to block tumor growth and proliferation [2, 3]. 
However, resistance still occurs, highlighting the need to 
develop alternative therapeutic approaches. In particular, 
mutations in KRAS, an oncogene with an important role in 
colon carcinogenesis, reportedly occur in 30% to 50% of 
CRCs and are frequently associated with resistance of mCRC 
to anti-EGFR therapies. Therefore, these therapies are only 
efficient in mCRC patients with wild type KRAS [4–8]. 
Autophagy has also emerged as a potential target for cancer 
therapy, as it has been implicated in the resistance of tumors 
to chemotherapy [9]. Autophagy is an evolutionary conserved 
catabolic process in eukaryotic cells from yeast to mammals 
that targets cellular components for lysosomal degradation 
to maintain cellular homeostasis [10]. Notably, cell lines 
harboring RAS mutations, such as those derived from bladder 
(T24, HRASG12V mutation), lung (H1299, NRASG12C mutation; 
H460, KRASQ61H mutation), pancreatic (PANC-1, KRASG12V 
mutation), and colorectal cancer (HCT116, KRASG13D 
mutation), have high basal levels of autophagy [11]. Indeed, 
several reports implicated RAS isoforms in autophagy 
regulation, with different outcomes in cancer progression 
depending on the cell type [11–17]. However, little is known 
about the role of KRAS mutations in autophagy regulation in 
CRC cells and the signaling pathways involved.
In this work, we aimed to understand the precise role 
of mutant KRAS alleles in autophagy. For this purpose, we 
established two original cell models for a controlled genetic 
background where the only difference is the KRAS variant they 
express: non-cancer colon cells derived from normal human 
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colon mucosal epithelium (NCM460) and a “humanized” 
Saccharomyces cerevisiae. The NCM460 cell line background 
does not contain KRAS mutations or deregulated pathways 
[18]. The yeast S. cerevisiae, a unicellular eukaryote highly 
amenable to manipulation and genetic modifications, 
is a well-established tool to study molecular aspects of 
different conserved biological processes, and a particularly 
advantageous system for heterologous expression [19, 20]. 
Moreover, autophagy-related (ATG) genes, responsible for the 
formation of the autophagosome, were first discovered in yeast 
and orthologues of many of these genes have been identified 
and characterized in higher eukaryotes, indicating that 
autophagy is a highly conserved pathway through evolution 
[21]. To transpose our findings to more clinically relevant 
cancer models, we used the reverse approach by silencing 
KRAS in two CRC-derived cell lines harboring different 
KRAS activating mutations. Here, we find that expression of 
mutant KRAS consistently increases autophagy in all models, 
which, in the colon cell lines, is associated with up-regulation 
of the MEK/ERK pathway. We also demonstrate that KRAS 
and autophagy support the survival of CRC cells exposed to 
stressful conditions like nutrient limitation. This suggests that 
inhibition of KRAS or autophagy may sensitize CRC cells 
harboring KRAS mutations to cancer therapies, reinforcing 
KRAS-induced autophagy inhibition as an emerging target for 
CRC therapeutic approaches.
RESULTS
KRAS mutations up-regulate autophagy during 
starvation in non-cancer colon cells and in a 
“KRAS-humanized yeast” model
To elucidate the role of oncogenic KRAS in 
autophagy regulation, we expressed FLAG-tagged wild-
type KRAS (KRASWT) or mutated KRAS (KRASG13D, 
KRASG12D and KRASG12V) in two model systems: in the 
human non-cancer colon NCM460 cell line, after stable 
infection, and in the yeast S. cerevisiae ras2∆ strain 
from the pCM184 plasmid, under the control of a tet-off 
promoter (this strain was chosen to abolish the input of 
yeast Ras2p, itself involved in autophagy regulation).
We first assessed the autophagic flux in NCM460 
cells, by monitoring the conversion of LC3-I into LC3-II, 
a hallmark of autophagy, in the presence and absence of 
Bafilomycin A1 (Baf. A1) [22]. Overexpression of FLAG-
KRASWT, -KRASG13D, -KRASG12D and -KRASG12V increased 
the basal level of LC3-II in complete medium, in comparison 
with parental NCM460 (non infected) cells (Figure 1a). 
During starvation, overexpression of FLAG-KRASG13D and 
-KRASG12D, but not of -KRASG12V, increased the autophagic 
flux in comparison with parental NCM460 and -KRASWT- 
expressing cells, as shown by the increased accumulation 
of LC3-II upon inhibition of lysosomal degradation by Baf. 
A1 (Figures 1a, 1b and Supplementary Figure S1a). Though 
these differences were consistent, variability was high and did 
not reach statis tical significance. We therefore quantitatively 
measured autophagic proteolysis of long-lived proteins 
radiolabeled with L-[14C]valine [23, 24]. In accordance with 
the previous assay, overexpression of FLAG-KRASG13D 
and -KRASG12D, but not -KRASG12V, increased the level of 
autophagic proteolysis, in comparison with parental NCM460 
and -KRASWT-expressing cells (Figures 1c and Supplementary 
Figure S1b). This increase was statistically significant in 
-KRASG13D-expressing cells, but in -KRASG12D- only when 
comparing with cells expressing -KRASWT (Figure 1c). Our 
results therefore indicate that some forms of mutated KRAS 
up-regulate autophagy in non-cancer colon cells.
In the S. cerevisiae model, autophagy levels were 
monitored by assessing the levels of the autophagic marker 
Atg8p, the yeast homologue of LC3, in the presence of 
the protease inhibitor PMSF to avoid degradation during 
the subsequent steps of the autophagy process [25]. No 
significant differences were observed in Atg8p levels 
between ras2∆ cells carrying the empty vector and ras2∆ 
cells expressing KRASWT, after 24 h of nitrogen starvation 
(Figures 1d and 1e). In contrast, expression of KRASG13D, 
KRASG12D and KRASG12V increased Atg8p levels under the 
same conditions (Figures 1d and 1e). These results show 
that activating KRAS mutations increase Atg8p levels more 
than wild-type KRAS in response to nitrogen starvation.
To confirm that the higher Atg8p levels detected 
were associated with induction of the autophagy flux, 
we also monitored the amount of Atg8p delivered to 
the vacuole. We transformed ras2∆ strains containing 
pCM184/KRAS plasmids or empty vector control with 
a GFP-ATG8 construct and monitored the degradation 
of GFP-Atg8 to free GFP by vacuolar hydrolases, which 
reflects the level of autophagy, by immunobloting [26]. 
We found no significant differences in the accumulation 
of free GFP between ras2∆ cells carrying the empty 
vector and ras2∆ cells expressing KRASWT, after 24 h 
of nitrogen starvation (Figures 1f and 1g). On the other 
hand, expression of KRASG13D, KRASG12D and KRASG12V 
increased the levels of the free GFP moiety after 24 h of 
nitrogen starvation (Figures 1f and 1g). KRAS protein 
levels were confirmed by immunoblot against this specific 
human RAS isoform (Figure 1f). These results indicate 
that mutated KRAS lead to a higher delivery of Atg8p into 
the yeast vacuole during starvation than wild-type KRAS.
Altogether, our results in both non-cancer colon 
and “KRAS-humanized yeast” models show that mutated 
KRAS up-regulate autophagy to a higher extent than wild-
type KRAS in response to nitrogen starvation, and validate 
both cell models to study the role of human KRAS 
proteins in the evolutionary conserved autophagic process.
Suppression of KRAS by RNA interference inhibits 
autophagy in HCT116 and SW480 cell lines
In order to confirm the aforementioned results obtained 
in yeast and NCM460 cells, we used cell lines derived 
from CRC patients and assessed whether suppression of 
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Figure 1: Activating KRAS mutations increase the autophagic flux during starvation, in NCM460 cells and S. 
cerevisiae. a. Immunoblot analysis of LC3-I/II in NCM460 cells and NCM460 cells expressing FLAG-KRASWT, FLAG-KRASG13D, 
FLAG-KRASG12D or FLAG-KRASG12V. LC3-I expression levels were too low to be detected. FLAG immunoblot was used as a control 
for expression of FLAG-tagged KRAS constructs. b. LC3II/Actin ratios were determined and used to calculate the autophagic flux by 
subtracting the normalized LC3-II levels in the absence of Baf. A1 from the corresponding levels obtained in the presence of Baf. A1, 
according to guidelines already published. [24] Results are means ± SEM of three independent experiments. c. Level of autophagic 
proteolysis during starvation in NCM460 cell lines. Cells were incubated with L-[14C]valine, and chased for 6 h in complete medium, 
HBSS or HBSS supplemented with 0.1 μM Baf. A1. The percentage of autophagic proteolysis was determined by subtracting the levels 
of proteolysis of cells incubated in HBSS in the absence of Baf. A1 from the corresponding levels of proteolysis of cells incubated in 
HBSS supplemented with Baf. A1. Values represent mean ± SEM of three independent experiments. ***P < 0.001 vs NCM460; ***P 
< 0.001, *P < 0.05 vs NCM460 FLAG-KRASWT; One-way ANOVA. d. Detection of Atg8p in the presence and absence of 1mM PMSF 
in S. cerevisiae ras2∆ cells expressing the empty vector pCM184, pCM184/KRASWT, pCM184/KRASG13D, pCM184/KRASG12D 
or pCM184/KRASG12V after 24h of nitrogen starvation (SD -N) and e. Atg8 T24 h -N/Atg8 T0 h -N ratio after normalization of Atg8 
to Pgk-1. (Continued )
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KRAS affects autophagy levels in HCT116 (KRASG13D) and 
SW480 (KRASG12V) cells. Indeed, suppression of KRAS by 
targeted small interference RNA (siRNA) in both cell lines 
significantly impaired the autophagic flux, evidenced by 
the decreased accumulation of LC3-II upon inhibition of 
lysosomal degradation by Baf. A1, whereas transfection 
with control siRNA did not (Figures 2a, 2b, Supplementary 
Figure S2a, 2c, 2d and Supplementary Figure S2b).
We next determined how depletion of KRAS 
affects the levels of other components of the autophagic 
machinery: the Atg5-Atg12 conjugate, a critical 
component of autophagosome formation [27], and Beclin 
1, a component of the class III PI3K complex (PI3KC3) 
that induces autophagosome formation [28]. Depletion of 
KRAS by siRNA in SW480 and HCT116 cells decreased 
the levels of Atg5-Atg12 conjugate and Beclin 1 in 
comparison with control siRNA- transfected cells, both 
in complete medium and starvation conditions (Figures 
2e–2j). Taken together, these data show that HCT116 and 
SW480 cells rely on KRASG13D and KRASG12V mutations, 
respectively, to maintain autophagy.
We also evaluated how manipulating the levels of 
mutant KRAS alleles in S. cerevisiae affects autophagy. For 
this purpose, cells grown in the absence of doxycycline 
(expressing KRAS) were transferred to nitrogen starvation 
media without or with doxycycline (to maintain or repress 
KRAS transcription, respectively) and the conversion of 
GFP-Atg8p to free GFP was monitored. As seen in Figures 
2k and Supplementary Figure S3a, activation of KRAS 
transcription during starvation increased the level of wild-
type KRAS, associated with an increase in the amount of 
free GFP generated, hence of autophagy induction. In turn, 
repression of wild-type KRAS transcription stabilized the 
level of KRAS protein and consequently the level of free GFP 
generated (Figures 2k and Supplementary Figure S3a). The 
same was not observed in yeast cells expressing KRASG13D, 
KRASG12D or KRASG12V. In these cells, nitrogen starvation 
maintaining KRAS expression also increased the levels of 
the respective KRAS variant, associated with accumulation 
of free GFP (Figures 2k, Supplementary Figure S3b, S3c 
and S3d). However, during repression of KRAS transcription, 
the level of KRAS proteins stabilized but the level of free 
GFP still increased (Figures 2k, Supplementary Figure 
S3b, S3c and S3d). Therefore, yeast cells harboring wild-
type KRAS depend on the amount of KRAS protein for 
autophagy induction, whereas those harboring activating 
KRASG13D, KRASG12D or KRASG12V do not. These results are 
consistent with constitutive activation of KRAS signaling 
due to the inability of mutated KRAS to hydrolyze GTP and 
consequently to be “switched off” [29–32], thus reproducing 
in the yeast background the effect of the aforementioned 
mutations on KRAS signaling.
These data also further support that KRAS mutations 
confer cells increased capacity for autophagy induction 
and that efficiently countering this effect can be achieved 
only by decreasing mutant KRAS protein levels below a 
certain threshold, as we observed in the CRC cell lines.
KRAS mutations induce autophagy through 
up-regulation of the ERK pathway
The MEK/ERK and the PI3K/AKT/mTOR pathways 
are the classical effectors of RAS, implicated in the 
regulation of various cellular responses known to generate 
resistance to CRC therapy [33]. We therefore analyzed 
how the KRAS variants affect the phosphorylation levels 
of ERK1/2 and AKT proteins in response to starvation. 
ERK phosphorylation increased in response to starvation 
in NCM460 cells overexpressing FLAG-KRASG13D, 
-KRASG12D and -KRASG12V, but not in parental NCM460 
or FLAG-KRASWT-expressing cells (Figures 3a and 3b). 
In contrast, starvation decreased AKT phosphorylation 
Figure 1: (Continued) Activating KRAS mutations increase the autophagic flux during starvation, in NCM460 
cells and S. cerevisiae. f. Free GFP generated from the GFP-Atg8p fusion protein in S. cerevisiae ras2∆ cells co-expressing GFP-
Atg8p with either empty vector pCM184, pCM184/KRASWT, pCM184/KRASG13D, pCM184/KRASG12D or pCM184/KRASG12V after 
24 h of nitrogen starvation, as shown by immunoblot analysis. KRAS immunoblot was used as a control for expression of human 
KRAS. Pgk-1 immunoblot was used as a loading control. g. Free GFP/Pgk-1 ratio at 24 h of nitrogen starvation, using ImageJ 
software. Values are means ± SEM of three independent experiments. **P < 0.01; *P < 0.05 one-way ANOVA followed by Tukey’s 
test vs pCM184/KRASWT.
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Figure 2: Suppression of KRAS in CRC- derived cell lines decreases autophagy. a. c. Immunoblot analysis of LC3-I/II, 
e. Atg5-Atg12 conjugate (using anti-Atg5 antibody) and Beclin 1 in HCT116 and SW480 cell lines. Cells were left non transfected 
(blank) or transfected with either siRNA control or siRNA targeted against KRAS. After 48 h of transfection, the cells were maintained 
in complete medium or incubated in HBSS medium (starvation) for further 6 h in presence and absence of 20 nM Baf A1. LC3-I 
expression levels were too small to be detected. KRAS immunoblot was used to show the efficient silencing by KRAS siRNA. Actin 
immunoblot was used as a loading control. All the protein bands showed in the lanes are from the same immunoblot despite being 
organized in different boxes. [24] b. d. LC3-II/Actin ratios determined using ImageJ software were used to determine the autophagic 
flux ratio of by subtracting the normalized LC3-II levels in the absence of Baf. A1 from the corresponding levels obtained in the 
presence of Baf. A1, according to guidelines already published. [24] f. Atg5-Atg12/Actin ratio and g. Beclin 1/Actin ratio of HCT116 
cells were determined using Image J software. Results are means ± SEM of three independent experiments. **P < 0.01; *P < 0.05 one-
way ANOVA followed by Tukey’s test. (Continued)
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in NCM460 expressing all KRAS variants, but not in 
parental cells, though not to a significant extent in the case 
of FLAG-KRASG13D (Figures 3a and 3c).
In agreement with the results obtained in NCM460 
cells overexpressing FLAG-KRASG13D and FLAG-
KRASG12V (Figure 3a), starvation also increased ERK 
phosphorylation in both HCT116 (KRAS G13D mutation) 
and SW480 (KRAS G12V mutation) cells (Figures 3d, 
3e, 3g and 3h). Accordingly, depletion of KRAS not 
only prevented this increase but also decreased ERK 
phosphorylation in non-starved cells (Figures 3d, 3e, 3g 
and 3h).
In HCT116 cells, AKT phosphorylation also 
mimicked the results obtained in the NCM460 
Figure 2: (Continued ) Suppression of KRAS in CRC- derived cell lines decreases autophagy. h. Atg5-Atg12 conjugate 
(using anti-Atg5 antibody) and Beclin 1 in SW480 cell lines. Cells were left non transfected (blank) or transfected with either siRNA 
control or siRNA targeted against KRAS. After 48 h of transfection, the cells were maintained in complete medium or incubated in HBSS 
medium (starvation) for further 6 h in presence and absence of 20 nM Baf A1. LC3-I expression levels were too small to be detected. KRAS 
immunoblot was used to show the efficient silencing by KRAS siRNA. Actin immunoblot was used as a loading control. All the protein 
bands showed in the lanes are from the same immunoblot despite being organized in different boxes. i. Atg5-Atg12/Actin ratio and j. Beclin 
1/Actin ratio of SW480 cells were determined using Image J software. Results are means ± SEM of three independent experiments. **P 
< 0.01; *P < 0.05 one-way ANOVA followed by Tukey’s test. k. Autophagy induction depends on the activating status of mutated KRAS 
activation during starvation in S. cerevisiae. KRAS/Pgk-1 and free GFP/Pgk-1 ratios of ras2∆ cells with/without expression of pCM184/
KRASWT, pCM184/KRASG13D, pCM184/KRASG12D or pCM184/KRASG12V. Cells were cultured in SC medium without the appropriate 
aminoacids + 2% glucose until exponential phase. At time 0, the cultures were subdivided: one part was incubated without doxycycline 
to maintain KRAS transcription active and another incubated with 10 μg/ml doxycycline to repress KRAS transcription. The level of 
free GFP generated and KRAS expression were assessed by immunoblot, at the indicated times and normalized for Pgk-1 using ImageJ 
software. Results are mean ± SEM of three independent experiments. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05 compared to 
the respective time point of cells non-treated with doxycycline.
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Figure 3: Mutated KRAS up-regulates ERK phosphorylation during starvation in normal and CRC- derived cells.  
a. Immunoblot analysis of pERK and pAKT in parental NCM460 and NCM460 cells infected with FLAG-KRASWT, FLAG-KRASG13D, 
FLAG-KRASG12D or FLAG-KRASG12V. Cells were grown at a density of 80% and were maintained in complete conditions or incubated in 
HBSS (starvation) medium for 6 h. Cell lysates were analyzed by immunoblot for the indicated proteins. FLAG immunoblot was used 
as a control for expression of FLAG-tagged KRAS constructs. Actin immunoblot was used as a loading control. The b. pERK/ERK and 
c. pAKT/AKT ratios determined using ImageJ software. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 one-way ANOVA followed 
by Tukey’s test. d. Immunoblot analysis of pERK and pAKT in HCT116 cells. Cells were left non transfected (blank) or transfected with 
either siRNA control or siRNA targeted against KRAS. 48 h after transfection, the cells were maintained in complete medium or incubated 
in HBSS medium (starvation) for further 6 h and cell lysates were analyzed by immunoblot for the indicated proteins. KRAS immunoblot 
was used to show the efficient silencing by siRNA KRAS. Actin immunoblot was used as a loading control. All the protein bands showed 
in the lanes are from the same immunoblot despite being organized in different boxes. e. pERK/ERK and f. pAKT/AKT ratios were 
determined using ImageJ software. Results are means ± SEM of three independent experiments. ***P < 0.001; **P < 0.01; *P < 0.05 
one-way ANOVA followed by Tukey’s test. (Continued )
Oncotarget30794www.impactjournals.com/oncotarget
FLAG-KRASG13D model: a slight but not significant 
decrease in control siRNA- transfected cells, and 
no difference in KRAS-depleted cells (Figures 
3d and 3f). In SW480 control siRNA- transfected 
cells, no statistical significance differences were 
obtained in rich medium. On the other hand, under 
starvation conditions, depletion of KRAS increased 
AKT phosphorylation in comparison control siRNA- 
transfected cells also in agreement with the NCM460 
FLAG-KRASG12V model (Figures 3g and 3i).
These data indicate that KRAS-induced 
autophagy is mediated through up-regulation of the 
MEK/ERK pathway and down-regulation of the 
PI3K/AKT pathway, known to activate the autophagy 
inhibitor mTOR [34], therefore resulting in autophagy 
induction. To confirm this hypothesis, we examined if 
these pathways affect starvation-induced accumulation 
of LC3-II after inhibition of lysosomal degradation 
by Baf. A1. In accordance with the aforementioned 
results, depletion of MEK1/2 by siRNA decreased the 
autophagic flux of SW480 cells, whereas depletion of 
PI3KCA had no effect (Figures 4a, 4b, Supplementary 
Figure S4a, 4c, 4d and Supplementary Figure S4b).
Taken together, our results indicate that oncogenic 
KRAS proteins activate autophagy through up-
regulation of the MEK/ERK pathway in non-cancer 
colon and CRC-derived cells, suggesting that autophagy 
plays an important role in KRAS-driven colorectal 
carcinogenesis.
Suppression of KRAS or autophagy leads to cell 
death in CRC-derived cells
To understand whether KRAS and/or autophagy 
are required for CRC cell survival, prompting a possible 
therapeutic approach, we analyzed how depletion of 
KRAS, ATG5 or BECN1 by siRNA affected cell death. We 
found that depletion of KRAS in SW480 cells increased 
the number of cells stained with annexin V (AV+ PI −/+, 
early apoptosis plus late apoptosis/necrosis) in comparison 
with control siRNA- transfected cells, particularly evident 
under starvation conditions (Figure 5). Depletion of ATG5 
or BECN1 (Supplementary Figure S5) had the same effect, 
though to a slightly lesser extent (Figure 5).
Taken together, our results show that KRAS-induced 
autophagy allows CRC-derived cells to survive in stressful 
conditions, such as nutrient limitation, as depletion 
of KRAS or impairment of the autophagic machinery 
promotes cell death of CRC cells.
DISCUSSION
In the present study, we analyzed the role of 
activating KRAS mutations on autophagy regulation in 
CRC. We established a non-cancer colon NCM460 cell 
model to study, in the same genetic background, the effect 
of overexpressing three of the most common mutant 
KRAS alleles that occur in CRCs: KRASG13D, KRASG12D 
and KRASG12V [35]. We show that autophagy is induced 
Figure 3: (Continued) Mutated KRAS up-regulates ERK phosphorylation during starvation in normal and CRC- derived 
cells. g. Immunoblot analysis of pERK and pAKT in SW480 cells. Cells were left non transfected (blank) or transfected with either siRNA 
control or siRNA targeted against KRAS. 48 h after transfection, the cells were maintained in complete medium or incubated in HBSS medium 
(starvation) for further 6 h and cell lysates were analyzed by immunoblot for the indicated proteins. KRAS immunoblot was used to show the 
efficient silencing by siRNA KRAS. Actin immunoblot was used as a loading control. All the protein bands showed in the lanes are from the same 
immunoblot despite being organized in different boxes. The h. pERK/ERK and i. pAKT/AKT ratios were determined using ImageJ software. 
Results are means ± SEM of three independent experiments. ***P < 0.001; **P < 0.01; *P < 0.05 one-way ANOVA followed by Tukey’s test.
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to a different extent depending on the mutant KRAS allele, 
since expression of KRASG13D and KRASG12D mutations 
up-regulated autophagy in NCM460 cells facing nutrient 
limitation, whereas wild-type KRAS or KRASG12V did not. 
In our “KRAS humanized yeast” system, KRASG13D and 
KRASG12D also induced autophagy in response to nitrogen 
starvation while wild-type KRAS did not. However, 
KRASG12V also highly up-regulated autophagy in this 
cell model. The lack of the genetic complexity found in 
human regulatory pathways and the lack of interference 
from wild-type KRAS and other human RAS family 
isoforms may explain the stronger phenotype observed 
in yeast compared with the human non-cancer colon 
cell model. Nonetheless, these results show that yeast 
is a particularly useful organism to address the function 
of KRAS in autophagy and that can be further explored 
to address other specific cellular functions of KRAS or 
KRAS localization within cellular compartments.
The results obtained in the yeast system show that 
expression of mutant KRAS per se can drive autophagy. 
Figure 4: Suppression of MEK1+MEK2, but not of PIK3CA, decreases autophagy in SW480 cells. Immunoblot analysis 
of LC3-I/II in SW480 cells, after suppression of a. MEK1 and MEK2 and c. PIK3CA. Cells were left non transfected (blank) or transfected 
with either control siRNA, siRNA targeted against MEK1 and MEK2 or siRNA targeted against PIK3CA. 48 h after transfection, the 
cells were maintained in complete medium or incubated in HBSS medium (starvation) for further 6 h and cell lysates were analyzed by 
immunoblot for the indicated proteins. MEK1/2 and PI3Kp110α immunoblot were used to show the efficient silencing by siRNA MEK1/2 
and siRNA PIK3CA, respectively. Actin immunoblot was used as a loading control. b. d. LC3-II/Actin ratios determined using ImageJ were 
used to calculate the autophagic flux by subtracting the normalized LC3-II levels in the absence of Baf A1 from the corresponding levels 
obtained in the presence of Baf A1. Results are means ± SEM of two independent experiments. *P < 0.05 one-way ANOVA followed by 
Tukey’s test.
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Figure 5: Suppression of KRAS, ATG5 and BECN1 promotes cell death in SW480. Cell death determined by Annexin V 
fluorescein isothiocyanate (AV-FITC) and propidium iodide (PI) assay in SW480 cells that were left non transfected (blank) or transfected 
with control siRNA, siRNA targeted against KRAS, ATG5 or BECN1. 24 h after transfection, cells were maintained in complete medium 
or incubated in HBSS medium (starvation) for another 24 h. Cells were fixed and double stained with Annexin V and PI before analyzed 
by flow cytometry. a. Representative histograms of SW480 cells double-labeled with AV and PI. b. Quantitative analysis of AV/PI staining 
in SW480 cells. Percentages of apoptotic cells (AV+) are the sum of the lower and upper right panels (AV+ PI+/-). Values represent mean 
±S.E.M. of at least three independent experiments. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001 comparing between each subset 
of cells (AV-PI-, AV-PI+; AV+ PI-/+). * vs Blank; # vs Control siRNA; + vs KRAS siRNA. Two-way ANOVA.
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However, the fact that expression of KRASG12V in 
NCM460 cells was not sufficient to up-regulate autophagy 
to the same extent as KRASG13D and KRASG12D, suggests 
other factors may also play a role, depending on the 
cellular background. Accordingly, recent studies reported 
that induced expression of HRASG12V and KRASG12V can 
up-regulate autophagy in several cell models, such as 
mice kidney iBMK [11], breast MCF10A epithelial cells 
[15, 16], ovarian HOSE epithelial cells, MCF-7 cells and 
HUVECs cells [12]. However, it had not been addressed 
whether inhibition of this mechanism has an effect in 
tumor cells. We determined that depletion of KRAS by 
siRNA impairs the autophagic flux of CRC- derived 
cell lines HCT116 and SW480, harboring KRASG13D 
and KRASG12V mutations, respectively, indicating that 
autophagy of CRC cells harboring KRAS mutations 
depends on KRAS.
The best-characterized RAS effector pathways 
involved in autophagy regulation are the MEK/ERK and 
the PI3K/AKT/mTOR signaling pathways [33], which are 
commonly deregulated in CRC [36, 37]. However, it is not 
known if/how KRAS modulates these effectors to regulate 
autophagy in CRC. Here, we demonstrate that KRAS-
induced autophagy is associated with up-regulation of 
ERK phosphorylation during nutrient limitation conditions 
in a non-cancer colon NCM460 cell model, consistent 
with a pro-autophagic role of MEK/ERK signaling [12, 
38]. In accordance, depletion of KRAS by siRNA in the 
two CRC- derived cell lines used decreased activation of 
ERK. We further show that activation of the MEK/ERK 
pathway is critical for autophagy in SW480 cells, since 
inhibiting MEK1/2 also significantly impaired this process. 
Overall, these results indicate that the MEK/ERK effector 
pathway is essential for KRAS-induced autophagy in CRC 
cells. However, activation of this pathway does not seem 
to be sufficient, since expression of KRASG12V in NCM460 
cells induced phosphorylation of ERK, like KRASG12D and 
KRASG13D, but did not up-regulate autophagy to a higher 
extent than wild-type KRAS, indicating KRAS may 
function through additional downstream effectors.
Overexpression of either KRAS variant in NCM460 
cells had the opposite effect on phosphorylation of AKT 
during nutrient limitation conditions, which tended 
to decrease. However, there was no correlation with 
autophagy induction; indeed, this decrease was most 
significant in cells overexpressing KRASWT and KRASG12V, 
which did not up-regulate autophagy. In agreement with 
the results obtained in the NCM460 model, depletion of 
KRAS in SW480 cells (KRASG12V mutation) increased AKT 
activation during starvation. Since depletion of KRAS in 
this cell line decreased autophagy, this could suggest an 
anti-autophagic role of PI3K/AKT/mTOR signaling in 
CRC [13]. However, the results obtained in the HCT116 
cell line, which displays constitutive activation of the 
AKT pathway due to an activating PIK3CAH1047R mutation, 
argue against this hypothesis. Indeed, on one hand 
autophagy is still induced in these cells; moreover, it is 
also decreased by depletion of KRAS, which is upstream 
of PI3K/AKT/mTOR. As expected, depletion of KRAS 
did not affect AKT activation in the HCT116 cell line, not 
only because these cells display constitutive activation 
of the AKT pathway, but also because overexpression of 
FLAG-KRASG13D in NCM460 cells did not affect pAKT 
levels. Overall, our results indicate the PI3K/AKT/mTOR 
pathway is not relevant in KRAS-induced autophagy. 
Accordingly, we found that depletion of PIK3CA did not 
affect autophagy induction of SW480 cells in response to 
starvation.
The interplay between RAS and autophagy on 
the survival of cancer cells is complex, as it may have 
both pro- and anti-tumorigenic roles. Previous studies 
demonstrated that expression of HRASG12V in MEFs and 
HRASG12V or KRASG12V in iBMK cells promotes cell 
proliferation through up-regulation of autophagy [11, 16, 
39]. Others showed that HRASG12V-induced autophagy 
contributes to cell death in HOSE, MCF-7 and HUVEC 
cells [12]. In our study, we sought to understand the effect 
of KRAS/autophagy inhibition on the cell death of CRC 
cells, which would attest to the clinical relevance of this 
process. We showed that depletion of KRAS, ATG5 or 
BECN1 results in cell death during growth of SW480 cells 
in complete medium, but to a higher extent in starvation 
conditions. These results indicate that autophagy mediated 
by activating KRAS mutations has a pro-survival role 
in CRC cells under stressful conditions, like nutrient 
deprivation.
EGFR inhibitors have been widely used in anti-
cancer therapy; however, they are inefficient in mCRCs 
harboring activating KRAS mutations, which remains an 
obstacle to the effective treatment of mCRC [4–8]. Despite 
continuous efforts, no successful therapy targeting KRAS 
has been developed and it remains an elusive target for 
cancer therapy. This is due to the lack of specificity of 
KRAS inhibitors and the fact that KRAS can overcome 
inhibition of these targeted therapies [40, 41]. Direct 
inhibition of KRAS using small interference RNA 
(siRNA) may be an alternative approach to the use of 
chemical inhibitors and our results support this hypothesis. 
However, in vivo delivery issues of siRNA have yet to be 
overcome for widespread clinical applications, although 
efforts are being made to develop siRNA therapeutic 
approaches using lipid nanoparticle delivery systems 
[42, 43]. An alternative approach is to target downstream 
KRAS signaling. Autophagy is implicated as a potential 
mechanism of resistance to anticancer agents, as it aids 
in the response of tumor cells to cellular stress and/or 
increased metabolic demands related to increased cell 
proliferation [44]. Our results suggest that inhibition of 
autophagy can be an alternative or possibly combined 
therapeutic approach for the treatment of CRCs harboring 
activating KRAS mutations that depend on autophagy 
for survival. Indeed, studies in colon cancer xenografts 
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using autophagy inhibitors in combination with 
chemotherapeutic agents showed that autophagy inhibition 
increases apoptosis accompanied by tumor regression 
[45]. Moreover, current clinical trials use the autophagy 
inhibitor hydroxychloroquine for treatment of a wide 
range of cancers, with promising results [46–50].
In summary, the results presented here contribute 
to a deeper understanding of the survival role of mutant 
KRAS alleles in CRC cells. We show that activating KRAS 
mutations increase autophagy in different cell models, 
and that this increase is mediated through activation of the 
MEK/ERK pathway in colon cells. We also demonstrate 
that inhibition of KRAS or autophagy can promote 
cell death in CRC cells harboring a KRAS mutation, 
highlighting KRAS-induced autophagy as an emerging 
target for CRC therapy.
MATERIALS AND METHODS
Cell lines and culture conditions
Cell lines used in this study were the noncancerous 
NCM460 cell line [18] and CRC-derived cell lines 
SW480 (KRASG12V mutation) and HCT116 (KRASG13D and 
PIK3CAH1047R mutations) [51] (ATCC). SW480 cells were 
grown in RPMI 1640 medium with glutamine (PAA, 
Austria) supplemented with 1% penicillin–streptomycin 
and 10% fetal bovine serum (FBS). HCT116 cells were 
grown in McCoy’s 5A (PAA, Austria) supplemented 
with 2 mM L-glutamine, 1% penicillin–streptomycin 
and 10% FBS. NCM460 cells were grown in M3:10TM 
(INCELL, San Antonio, TX). All cell lines were cultured 
in a humidified incubator with 5% CO2 at 37°C. To 
assess basal protein levels, cells were cultured in 
complete medium and collected at 80% of confluence. 
For autophagy induction, cells growing in complete 
medium were washed three times with 1x PBS and 
incubated for 6 hours in Hank’s Buffered Salt Solution 
(HBSS) buffered with 2.2 g/l NaHCO3. Bafilomycin A1 
was added to inhibit lysosomal degradation in order to 
anaanalyze3-I/II protein levels (at 20 nM) or autophagic 
proteolysis (at 100 nM).
Production of lentivirus containing KRAS genes 
and lentiviral infection
The human wild-type KRAS mRNA sequence was 
cloned into a pLenti6/V5 Directional TOPO® (Invitrogen), 
giving rise to the KRASWT expression vector. KRASG13D, 
KRASG12D or KRASG12V mutant vectors were obtained by 
site-directed mutagenesis using specific primer sequences 
for each mutation. These vectors were used as templates 
to subclone wild-type and KRAS mutant sequences 
into the p3XFLAG-CMV vector to create FLAG-
KRAS constructs before generating HIV-1 lentivirus-
based vectors. A 5′ NheI site and a 3′PstI site were 
introduced in the FLAG-KRAS sequence by PCR using 
p3XFLAG-CMV KRAS as a template and primers 5′-T 
TTGCTAGCATGGACTACAAAGACCATGACGG-3′ 
and 5′-TTTCTGCAGCTACATAATTACACACTTTGTC 
TT TGAC-3′. The PCR product was sub-cloned between 
the NheI and PstI sites in pRRLSIN.cPPT.PGK.MSC.
WPRE lentivector. Correct integration of FLAG-KRAS 
constructs was confirmed by sequencing. HEK-293FT 
cells were used as packaging cells, and virus production 
was as previously described [52]. NCM460 cells were 
infected with the lentiviral constructs pRR/FLAG-
KRAS in complete medium, and cells collected after 
5 days of infection. Infection with FLAG-KRAS was 
confirmed by immunofluorescence and by immunoblot 
of protein extracts, using an anti-FLAG primary antibody 
(Supplementary Figures S6a and S6b). All experiments 
using these cells were performed between the 4th and 8th 
weeks after infection. Population doubling determination 
showed a stable growth of cells with constitutive 
expression of FLAG-KRASWT, -KRASG13D, -KRASG12D or 
-KRASG12V (Supplementary Figure S6c).
RNA silencing
HCT116 and SW480 cells were transiently 
transfected with siRNA using Lipofectamine 2000 
(Invitrogen), according to manufacturer recommendations. 
siRNAs used were: KRAS siRNA (Hs_KRAS2_8), 
ATG5 siRNA (Hs_APG5L_6) and BECN1 siRNA (Hs_
BECN1_5) designed by Qiagen; and MAP2K1 siRNA (L-
003571-00-0010), MAP2K2 siRNA (L-003573-00-0010) 
and PIK3CA siRNA (L-003018-00-0010), designed by 
Dharmacon.
Determination of long-lived protein degradation
Parental NCM460 cells and NCM460 cells infected 
with FLAG-KRAS constructs were labeled for 24 hours in 
complete medium containing 0.1 μCi L-[14C]valine/ml/well. 
After 24 hours, cells were washed three times with 1x PBS 
and radioactivity was pre-chased for 1 hour in complete 
medium in the presence of an excess of L-valine (10 mM) to 
remove the contribution of short-lived protein degradation. 
Cells were washed three times with 1x PBS, incubated 
for 6 hours either in complete medium or in HBSS in the 
presence or absence of Baf. A1 (0,1 μM) and with an excess 
of L-valine (10 mM). Supernatants were collected and free 
amino acids precipitated with 80% trichloroacetic acid 
(TCA), while proteins in adherent cells were precipitated 
with 10% TCA. The two fractions were transferred to vials 
containing 3 ml OptiPhase HiSafe II scintillation liquid 
(LKB Scintillation Products). Radioactivity was quantified 
in a liquid scintillation counter Packard Tri-Carb 2200 
CA (Packard Instrument). Proteolysis was calculated as a 
percentage of the radioactivity in the supernatant relative to 
the total cell radioactivity.
Oncotarget30799www.impactjournals.com/oncotarget
Annexin V/PI assay
SW480 cells were maintained in complete medium 
or incubated with HBSS medium. After 24 h of treatment, 
both suspended and attached cells were collected and 
washed in 1x PBS. 1×106 cells were resuspended in 100 μl 
1x binding buffer and incubated with 5 μl AV-fluorescein 
isothiocyanate (BD Biosciences, San Jose, CA, USA) and 
10 μl 50 μg/ml PI for 15 min in the dark. Samples were 
analyzed in an Epics® XL™ (Beckman Coulter) flow 
cytometer, equipped with an argon-ion laser emitting a 
488-nm beam at 15 mW. Monoparametric detection of red 
fluorescence was performed using FL-4 (488/675 nm) and 
detection of green fluorescence was performed using FL-1 
(488/525 nm). 20 000 cells were analyzed per sample and 
data analyzed using FlowJo software (version 7.6, Tree 
Star Inc., Ashland, OR, USA).
Yeast plasmids
KRASWT, KRASG13D, KRASG12D or KRASG12V were sub-
cloned as a BamHI-ApaI fragments from pLenti6/V5-D-
TOPO (Invitrogen) and inserted between the BamHI and ApaI 
sites of pCM184 (TRP1) yeast plasmid, under the control of 
a tet-off promoter (repressed by the addition of doxycycline). 
The GFP-Atg8p (URA3) construct, for expression of ATG8 
under the control of its endogenous promoter in the pRS416 
plasmid, was previously described [26].
Yeast strains
The Saccharomyces cerevisiae mutant strain W303-
1B ras2Δ pho8Δ60 was generated by transformation of 
parental strain W303-1B pho8Δ60 [53] with a disruption 
cassette amplified by PCR from genomic DNA of the 
BY4741 ras2Δ strain (Euroscarf). Correct integration 
of the cassette was confirmed by colony PCR. W303-
1B ras2Δ pho8Δ60 was co-transformed with pCM184/
KRAS variants and pGFP-Atg8, and the resulting 
transformants grown in selective media lacking the 
appropriate amino acids. KRAS expression was confirmed 
by immunoblot against KRAS (Supplementary Figure 
S6d). No differences in growth of S. cerevisiae ras2∆ cells 
transformed either with empty vector or pCM184/KRAS 
variants were observed (Supplementary Figure S6e).
Growth conditions
Yeast cells were grown aerobically in synthetic 
complete medium [SC; 0.17% yeast nitrogen base w/o amino 
acids and ammonium sulphate (Difco), 0.5% ammonium 
sulphate, 0.1% potassium phosphate, 0.2% Drop-out Mix 
and 0.01% auxotrophic requirements, pH 5.5] supplemented 
with 2% glucose in the presence of 10 μg ml-1 doxycycline. 
Cells were harvested, washed three times with water and 
resuspended in fresh medium without doxycycline to induce 
KRAS expression. For KRAS repression assays, 10 μg/
ml doxycycline was added to the cultures to inhibit KRAS 
transcription. For nitrogen starvation assays, cells were grown 
in SC media without doxycycline until exponential phase, 
washed twice with distilled sterile water and suspended in 
nitrogen starvation media [SD-N; 0.17% yeast nitrogen 
base w/o amino acids and ammonium sulphate (Difco)] 
supplemented with 2% glucose for 24 h. All incubations were 
performed at 30°C, 200 r.p.m.
Immunoblot analysis
Preparation of total protein extracts of human cell 
lines was performed as described in ref. [54]. Preparation of 
total protein extracts of yeast cells, SDS-PAGE and Western 
blots were performed as previously described [55].
Antibodies
Antibodies used were: anti-actin, anti-Atg5, anti-
LC3 and anti-FLAG (Sigma); anti-KRAS, and anti-yeast 
Atg8p (Santa-Cruz Biotechnology); anti-Beclin1, anti-
phospho p44/42 MAPK (Thr202/Tyr204), anti-p44/42 
total, anti-phospho Akt (Ser473), anti-Akt total, anti-
PI3Kp110α, anti-phospho MEK1/2 and anti-MEK1/2 
total (Cell Signalling); anti-yeast phosphoglycerate kinase 
(Pgk-1) (Molecular Probes); and mouse monoclonal GFP 
(1:3000; Roche Applied Science).
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